Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

26-10-2023 | Hematologic Cancer | News

ESMO 2023

New immunotherapeutic approach for recurrent/refractory hematologic cancers

Login to get access

MedNet.nl: Activation of γ9δ2 T cells by the monoclonal antibody ICT01 has the potential to become a novel immunotherapeutic approach for relapsing/refractory hematologic cancers. This is stated by researchers based on the results of the EVICTION study.

Related topics

ESMO 2023 rotated-square
Cancer Immunotherapy rotated-square
Acute Myeloid Leukemia rotated-square
Diffuse Large B-Cell Lymphoma rotated-square
Non-Hodgkin Lymphoma rotated-square
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits